Table 1.
Characteristics of the Participants at Enrollment
| Group | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|---|---|---|---|---|---|---|---|---|---|
| Primary EUA Immunization Vaccine | Janssen Ad26.COV2-S 5×1010 vp |
Moderna mRNA-1273 100-mcg |
Pfizer/BioNTech BNT162b2 30-mcg |
Janssen Ad26.COV2-S 5×1010 vp |
Moderna mRNA-1273 100-mcg |
Pfizer/BioNTech BNT162b2 30-mcg |
Janssen Ad26.COV2-S 5×1010 vp |
Moderna mRNA-1273 100-mcg |
Pfizer/BioNTech BNT162b2 30-mcg |
| Booster | Moderna mRNA-1273 100-mcg | Janssen Ad26.COV2-S 5×1010 vp | Pfizer/BioNTech BNT162b2 30-mcg | ||||||
| Total Number | 53 | 51 | 50 | 50 | 49 | 51 | 53* | 51 | 50 |
| Sex - no. (%) | |||||||||
| Female | 26 (49.1) | 32 (62.7) | 29 (58.0) | 27 (46.0) | 16 (32.7) | 23 (45.1) | 29 (54.7) | 26 (51.0) | 23 (46.0) |
| Male | 27 (50.9) | 19 (37.3) | 21 (42.0) | 23 (54.0) | 33 (67.3) | 28 (54.9) | 24 (45.3) | 25 (49.0) | 27 (54.0) |
| Age - years | |||||||||
| Mean (s.d.) | 56.8 (14.5) | 53.1 (16.2) | 54.8 (17.4) | 50.1 (13.9) | 49.9 (16.8) | 50.3 (15.4) | 47.7 (14.5) | 54.3 (16.8) | 50.4 (17.9) |
| Range | 24–81 | 24–76 | 22–85 | 24–77 | 20–75 | 20–76 | 22–74 | 23–75 | 19–80 |
| Race - no. (%) | |||||||||
| Asian | 4 (7.5) | 5 (9.8) | 4 (8.0) | 3 (6.0) | 5 (10.2) | 6 (11.8) | 1 (1.9) | 2 (3.9) | 1 (2.0) |
| Hawaiian or Pacific Islander | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.9) | 0 (0.0) | 0 (0.0) |
| Black/African American | 1 (1.9) | 2 (3.9) | 3 (6.0) | 0 (0.0) | 0 (0.0) | 2(3.9) | 0 (0.0) | 2 (3.9) | 1 (2.0) |
| White | 46 (86.8) | 41 (80.4) | 43 (86.0) | 44 (88.0) | 43 (87.8) | 40 (78.4) | 50(94.3) | 47 (92.2) | 43 (86.0) |
| Multi-racial | 1 (1.9) | 3 (5.9) | 0 (0.0) | 3 (6.0) | 1 (2.0) | 2 (3.9) | 1 (1.9) | 0 (0.0) | 4 (8.0) |
| Other | 1 (1.9%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.0%) | 0 (0.0) | 0 (0.0) | 1 (2.0%) |
| Ethnicity - no (%) | |||||||||
| Non-Hispanic | 49 (92.5) | 46 (90.2) | 47 (94.0) | 47 (94.0) | 49 (100.0) | 48 (94.1) | 51 (96.2) | 49 (96.1) | 45 (90.0) |
| Hispanic/Latino | 4 (7.5) | 4 (7.8) | 3 (6.0) | 2 (4.0) | 0 (0.0) | 3 (5.9) | 2 (3.8) | 2 (3.9) | 5 (10.0) |
| Unknown/Not reported | 0 (0.0) | 1 (2.0) | 0 (0.0) | 1 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Boost Interval weeks | |||||||||
| Mean (s.d.) | 13.7 (1.0) | 16.4 (1.9) | 16.8 (2.2) | 17.7 (2.0) | 19.3 (4.2) | 20.6 (5.8) | 19.9 (2.5) | 22.9 (4.6) | 24.1 (5.2) |
| Range | 12.0–15.9 | 12.4–20.0 | 12.0–20.9 | 13.9–21.0 | 12.6–26.0 | 12.3–41.3 | 10.9–23.0 | 12.6–28.7 | 14.3–31.9 |
*
Includes one participant with early termination from the Study at Day 1 visit and who did not receive a booster vaccination.